Aspire Growth Partners LLC Takes $592,000 Position in Pfizer Inc. (NYSE:PFE)

Aspire Growth Partners LLC bought a new position in shares of Pfizer Inc. (NYSE:PFE) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 22,333 shares of the biopharmaceutical company’s stock, valued at approximately $592,000.

Other hedge funds have also recently bought and sold shares of the company. Retirement Wealth Solutions LLC bought a new stake in shares of Pfizer during the fourth quarter worth $26,000. Rialto Wealth Management LLC bought a new position in Pfizer during the 4th quarter worth about $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Pfizer in the 4th quarter valued at about $28,000. Noble Wealth Management PBC bought a new stake in shares of Pfizer in the fourth quarter valued at about $31,000. Finally, Curio Wealth LLC acquired a new position in shares of Pfizer during the fourth quarter worth about $32,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Pfizer

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.06% of the company’s stock.

Pfizer Stock Performance

Shares of NYSE PFE opened at $24.19 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $137.19 billion, a P/E ratio of 17.16, a P/E/G ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The stock has a 50 day moving average of $24.34 and a 200-day moving average of $25.78.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. The firm had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company’s quarterly revenue was down 7.8% on a year-over-year basis. During the same period in the previous year, the company earned $0.82 earnings per share. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 7.11%. Pfizer’s dividend payout ratio (DPR) is presently 124.64%.

Analysts Set New Price Targets

Several research firms have commented on PFE. The Goldman Sachs Group restated a “neutral” rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Citigroup restated a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Cantor Fitzgerald started coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price objective for the company. Finally, Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.